RXi Pharmaceuticals Corporation, an RNA-targeted technologies company, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period. This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side.
Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days.
Multiple dermal injections were well tolerated at all doses and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study. These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Are Marijuana Warning Labels Needed? Users Say Yes
- Should Pregnant Women Be Concerned About BPA?
- Something is wrong in the Arctic
- Order Patterned With Chaos - How Climate Is Predicted For Decades - With Exact Forecasts Only For Days
- The Five Stages Of A Dying Theory
- Is The X(5568) A True Resonance ?
- John Glenn, Astronaut, and Senator dead at 95. A Milennial Perspective
- "I was an avid reader of sci-fi and of non-fiction books about space exploration. I may have..."
- "I imagine a conversation something like this -Space agency executive: OK, John, we want you to..."
- "Vaughn A: thanks for your contribution.This swap-over effect was predicted back in about 1958. ..."
- "Emmanuel: if you use Microsoft Word to write an article, then copy it into science 2.0 like..."
- "No, not at all. I just posted there:..."
- Child Mummy May Change Timeline for Smallpox
- On Proposed Tanning Bed Ban for Teens, New Study Urges FDA to Act
- It’s Not Brain Surgery, But do you Know What is? Brain Surgery!
- A Possible Antidote for Carbon Monoxide Poisoning
- Surgeon General Declares War on E-Cigarettes But Not Marijuana, Hookah
- NHL's Concussion Protocol, a Closer Look (Part 2)